Kevin E. Healy

Valitor, Inc. develops a new generation of biotechnology drugs. It develops methods of modifying therapeutic proteins to achieve substantial control over pharmacokinetics, target specificity and bioactivity. The company was founded by Kevin E. Healy, Wesley M. Jackson and David Schaffer in 2010 and is headquartered in Berkeley, CA.

Valitor, Inc. develops a new generation of biotechnology drugs. It develops methods of modifying therapeutic proteins to achieve substantial control over pharmacokinetics, target specificity and bioactivity. The company was founded by Kevin E. Healy, Wesley M. Jackson and David Schaffer in 2010 and is headquartered in Berkeley, CA.

Valitor, Inc. develops a new generation of biotechnology drugs. It develops methods of modifying therapeutic proteins to achieve substantial control over pharmacokinetics, target specificity and bioactivity. The company was founded by Kevin E. Healy, Wesley M. Jackson and David Schaffer in 2010 and is headquartered in Berkeley, CA.

Valitor, Inc. develops a new generation of biotechnology drugs. It develops methods of modifying therapeutic proteins to achieve substantial control over pharmacokinetics, target specificity and bioactivity. The company was founded by Kevin E. Healy, Wesley M. Jackson and David Schaffer in 2010 and is headquartered in Berkeley, CA.